Literature DB >> 18230794

Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Andrew W Roddam, Naomi E Allen, Paul Appleby, Timothy J Key.   

Abstract

BACKGROUND: Sex hormones in serum have been hypothesized to influence the risk of prostate cancer. We performed a collaborative analysis of the existing worldwide epidemiologic data to examine these associations in a uniform manner and to provide more precise estimates of risks.
METHODS: Data on serum concentrations of sex hormones from 18 prospective studies that included 3886 men with incident prostate cancer and 6438 control subjects were pooled by the Endogenous Hormones and Prostate Cancer Collaborative Group. Relative risks (RRs) of prostate cancer by fifths of serum hormone concentration were estimated by use of conditional logistic regression with stratification by study, age at recruitment, and year of recruitment. All statistical tests were two-sided.
RESULTS: No associations were found between the risk of prostate cancer and serum concentrations of testosterone, calculated free testosterone, dihydrotestosterone, dehydroepiandrosterone sulfate, androstenedione, androstanediol glucuronide, estradiol, or calculated free estradiol. The serum concentration of sex hormone-binding globulin was modestly inversely associated with prostate cancer risk (RR in the highest vs lowest fifth = 0.86, 95% confidence interval = 0.75 to 0.98; P(trend) = .01). There was no statistical evidence of heterogeneity among studies, and adjustment for potential confounders made little difference to the risk estimates.
CONCLUSIONS: In this collaborative analysis of the worldwide data on endogenous hormones and prostate cancer risk, serum concentrations of sex hormones were not associated with the risk of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18230794      PMCID: PMC6126902          DOI: 10.1093/jnci/djm323

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  51 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Androgen metabolism in men receiving finasteride before prostatectomy.

Authors:  R W Norman; K E Coakes; A S Wright; R S Rittmaster
Journal:  J Urol       Date:  1993-11       Impact factor: 7.450

3.  5 alpha-reductase activity and prostate cancer: a case-control study using stored sera.

Authors:  H A Guess; G D Friedman; M C Sadler; F Z Stanczyk; J H Vogelman; J Imperato-McGinley; R A Lobo; N Orentreich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-01       Impact factor: 4.254

Review 4.  The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.

Authors:  Elizabeth A Platz; Edward Giovannucci
Journal:  J Steroid Biochem Mol Biol       Date:  2005-01-05       Impact factor: 4.292

5.  Hormonal predictors of prostate cancer: a meta-analysis.

Authors:  T Shaneyfelt; R Husein; G Bubley; C S Mantzoros
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

6.  Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men.

Authors:  A Vermeulen; G Verdonck
Journal:  J Clin Endocrinol Metab       Date:  1992-04       Impact factor: 5.958

7.  The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate.

Authors:  G W Comstock; G B Gordon; A W Hsing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 May-Jun       Impact factor: 4.254

8.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

Authors:  Gerrit Draisma; Rob Boer; Suzie J Otto; Ingrid W van der Cruijsen; Ronald A M Damhuis; Fritz H Schröder; Harry J de Koning
Journal:  J Natl Cancer Inst       Date:  2003-06-18       Impact factor: 13.506

9.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

10.  Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition.

Authors:  Ruth C Travis; Timothy J Key; Naomi E Allen; Paul N Appleby; Andrew W Roddam; Sabina Rinaldi; Lars Egevad; Peter H Gann; Sabine Rohrmann; Jakob Linseisen; Tobias Pischon; Heiner Boeing; Nina Føns Johnsen; Anne Tjønneland; Kim Overvad; Lambertus Kiemeney; H Bas Bueno-de-Mesquita; Sheila Bingham; Kay-Tee Khaw; Rosario Tumino; Sabina Sieri; Paolo Vineis; Domenico Palli; José Ramón Quirós; Eva Ardanaz; Maria-Dolores Chirlaque; Nerea Larrañaga; Carlos Gonzalez; Maria-José Sanchez; Antonia Trichopoulou; Chrysa Bikou; Dimitrios Trichopoulos; Pär Stattin; Mazda Jenab; Pietro Ferrari; Nadia Slimani; Elio Riboli; Rudolf Kaaks
Journal:  Int J Cancer       Date:  2007-09-15       Impact factor: 7.396

View more
  215 in total

1.  Sex hormones and the risk of incident prostate cancer.

Authors:  Nicholas A Daniels; Carrie M Nielson; Andrew R Hoffman; Douglas C Bauer
Journal:  Urology       Date:  2010-05-07       Impact factor: 2.649

2.  The effect of physiological concentrations of sex hormones, insulin, and glucagon on growth of breast and prostate cells supplemented with unmodified human serum.

Authors:  Amin Esfahani; Cyril W C Kendall; Balachandran Bashyam; Michael C Archer; David J A Jenkins
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-10-07       Impact factor: 2.416

3.  A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

Authors:  Sara Lindström; Jing Ma; David Altshuler; Edward Giovannucci; Elio Riboli; Demetrius Albanes; Naomi E Allen; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Stephen J Chanock; Alison M Dunning; Heather Spencer Feigelson; J Michael Gaziano; Christopher A Haiman; Richard B Hayes; Brian E Henderson; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loic Le Marchand; Carmen Martínez; Kim Overvad; Afshan Siddiq; Meir Stampfer; Pär Stattin; Daniel O Stram; Michael J Thun; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Meredith Yeager; Peter Kraft; Matthew L Freedman
Journal:  J Clin Endocrinol Metab       Date:  2010-06-09       Impact factor: 5.958

4.  Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Authors:  Andrea Salonia; Andrea Gallina; Firas Abdollah; Alberto Briganti; Umberto Capitanio; Nazareno Suardi; Matteo Ferrari; Marco Raber; Renzo Colombo; Massimo Freschi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2011-09-21       Impact factor: 4.226

5.  Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

Authors:  Eduard García-Cruz; Jorge Huguet; Marta Piqueras; Meritxell Pérez Márquez; Lluís Peri; Laura Izquierdo; Agustín Franco; Ricardo Alvarez-Vijande; María José Ribal; Antonio Alcaraz
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

Review 6.  Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline.

Authors:  Alvaro Morales; Richard A Bebb; Priya Manjoo; Peter Assimakopoulos; John Axler; Christine Collier; Stacy Elliott; Larry Goldenberg; Irv Gottesman; Ethan D Grober; Gordon H Guyatt; Daniel T Holmes; Jay C Lee
Journal:  CMAJ       Date:  2015-10-26       Impact factor: 8.262

7.  The effects of cigarette smoking on prostate-specific antigen in two different age groups.

Authors:  Gokhan Koc; Korhan Akgul; Yuksel Yilmaz; Alper Dirik; Sitki Un
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

8.  Male pattern baldness in relation to prostate cancer risks: an analysis in the VITamins and lifestyle (VITAL) cohort study.

Authors:  Cindy Ke Zhou; Alyson J Littman; Paul H Levine; Heather J Hoffman; Sean D Cleary; Emily White; Michael B Cook
Journal:  Prostate       Date:  2014-12-09       Impact factor: 4.104

9.  Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer.

Authors:  Sarah B Peskoe; Corinne E Joshu; Sabine Rohrmann; Katherine A McGlynn; Sarah J Nyante; Gary Bradwin; Adrian S Dobs; Norma Kanarek; William G Nelson; Elizabeth A Platz
Journal:  Prostate       Date:  2015-04-28       Impact factor: 4.104

10.  Malignancy risk in Korean male patients with ankylosing spondylitis.

Authors:  Bora Nam; Hyoungyoung Kim; Eun Jin Jang; Soo-Kyung Cho; Yoon-Kyoung Sung; Tae-Hwan Kim
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.